# Immutep

Source: https://onco.cc/companies/immutep/  
OnCo record `immutep` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Immutep is an Australian-French company built on the immune checkpoint LAG-3, whose soluble LAG-3 protein eftilagimod alpha is in the phase 3 TACTI-004 trial with pembrolizumab and chemotherapy in first-line non-small-cell lung cancer.

## Summary

Immutep, listed in Sydney and on Nasdaq and with research in Paris, develops therapies around LAG-3, a checkpoint discovered by its scientific founder. Its lead, eftilagimod alpha (efti), is a soluble LAG-3 protein that activates antigen-presenting cells through MHC class II rather than blocking a checkpoint, and is combined with PD-1 antibodies and chemotherapy; after phase 2 results in lung and head and neck cancer it began the phase 3 TACTI-004 trial in first-line non-small-cell lung cancer in 2025. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Immutep S.A.S.; Immutep Limited; Prima BioMed
- Tags: ctgov-sponsor
- HQ: Sydney
- Type: biotech
- Website: https://www.immutep.com

## Sources

- Official website: https://www.immutep.com
- ClinicalTrials.gov: trials led by Immutep: https://clinicaltrials.gov/search?lead=Immutep
- Wikipedia: https://en.wikipedia.org/wiki/Immutep

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- targets: [LAG-3](https://onco.cc/targets/lag3/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/immutep.json